

INFORMAȚII PERSONALE

PASCA FENESAN MIHAELA MARIA

 0256204250, INT.1484 fenesan.mihaela@gmail.com, mihaela.fenesan@umft.ro

Sexul Feminin | Naționalitatea Romana

EXPERIENȚA PROFESIONALĂ

09.2023-Prezent

Medic primar Oncologie Medicală
Clinica Oncohelp, Timisoara

10.2022-Prezent

Asistent universitar doctorand
Catedra Universitara Histologie
Universitatea de Medicina si Farmacie Victor Babes Timisoara

06.2018-09.2023

Medic specialist Oncologie Medicală
Clinica Oncohelp, Timisoara

01.2013-06.2018

Medic rezident Oncologie Medicală
Spitalul Clinic Municipal de Urgenta Timisoara
Clinica Oncohelp, Timisoara

EDUCAȚIE ȘI FORMARE

10.2020-Prezent

Student doctorand
Universitatea de Medicina si Farmacie Victor Babes Timisoara

01.2013-03.2018

Rezidentiat in specialitatea Oncologie Medicală
Spital Clinic Municipal de Urgenta Timisoara
Clinica Oncohelp, Timisoara

10.2006-09.2012

Doctor medic
Universitatea de Medicina si Farmacie Victor Babes Timisoara

09.2002-06.2006

Liceul Hercules Baile-Herculane, jud.Caras-Severin
Clasa Matematica Informatica

Limba(i) maternă(e) Romana

Alte limbi străine cunoscute

	INTELEGERE		VORBIRE		SCRIERE
	Ascultare	Citire	Participare la conversație	Discurs oral	
Engleza	C1	C1	B2	B2	B2
Franceza	B2	B2	B2	B2	B2

PUBLICATII

1.) Heterogeneity of the Alpha-Smooth Muscle Actin Tumor Score in Breast Cancer Cells Significantly Affects Tumor Invasiveness, Recurrence, and Patient Survival

Mihaela-Maria Pasca Fenesan • Andrei Alexandru Cosma • Eugen Melnic • Anca Maria Cimpean • Gabriel Veniamin Cozma • Alina Gabriela Negru

Cureus 16(12): e75908. doi:10.7759/cureus.75908

2.) Predictive Factors for Multiple Metastases of Clear Cell Renal Cell Carcinoma

AA COSMA, AG NEGRU, OC FERICIAN, MM PASCA FENESAN, V VORNICU, AM FERICIAN, E MELNIC and AM CIMPEAN

2025-Jun.Anticancer research 45 (6) , pp.2365-2375; DOI: <https://doi.org/10.21873/anticanres.17609>

3.) Insights into the Multidisciplinary Approach for Metastatic Acinic Cell Lung Carcinoma: The Pathologist's Role in Romania Today

D.C.Lazureanu, A.Burlea, R.Barna, D.Cipu, M.Pasca Fenesan, I.Icma and M.Cornianu

Curr. Oncol. 2025, 32(1), 37; <https://doi.org/10.3390/currenol32010037>

4.) Tissue Prognostic Markers for Clear Cell Renal Cell Carcinoma Tumor-stroma Interaction: Impact on TNM Staging Parameters

AA COSMA, AG NEGRU, OC FERICIAN, MM PASCA FENESAN, V VORNICU, AM FERICIAN, E MELNIC and AM CIMPEAN

Anticancer Research June 2025, 45 (6) 2401-2416; DOI: <https://doi.org/10.21873/anticanres.17612>

5.) Combining RNAscope, Immunohistochemistry (IHC) and Digital Image Analysis to Assess Podoplanin (PDPN) Protein and PDPN mRNA Expression on Formalin-Fixed Paraffin- Embedded Normal Human Placenta Tissues

Tomescu, L.C.;Cosma, A.A.Fenesan,M.P;Melnic, E;Petrovici,V;Sarbu,S;Chis,M;Sas,I;Ribatti,D.Cimpean,A.M

Curr. Issues Mol. Biol. 2024, 46(6), 5161-5177; <https://doi.org/10.3390/cimb46060310>

6.) Exploring vasculogenesis in the normal human kidney and clear cell renal cell carcinoma: insights from development to tumor progression and biomarkers for therapy response

Cosma AA, Fenesan MP, Nesi A, Melnic E, Ferician AM, Ferician OC, Ceban E, Sarb S and Cimpean AM

Front. Oncol., 30 April 2024; Sec. Molecular and Cellular Oncology; Volume 14 - 2024 | <https://doi.org/10.3389/fonc.2024.1375190>

7.) Validation of Human Bone Marrow-derived Mesenchymal Stem Cells and MCF-7 Breast Cancer Cells Co-culture Using a 3D Perfused Biomimetic Microfluidic Platform

AM CIMPEAN, S COMSA, A STURZA, AC BARB, AA COSMA, M PASCA FENESAN, C IONESCU, AM ILE, S SARB, M CHIS

Anticancer Research April 2024, 44 (4) 1441-1453; DOI: <https://doi.org/10.21873/anticanres.16940>

8.) Artificial Intelligence (AI) Based Analysis of In Vivo Polymers and Collagen Scaffolds Inducing Vascularization

ER SALVANTE, AV POPOIU, AC BARB, AA COSMA, MP FENESAN, TA POPOIU, BD CAPLAR, FR DOROBANTU, AM CIMPEAN

In Vivo March 2024, 38 (2) 620-629; DOI: <https://doi.org/10.21873/invivo.13481>

9.) Age, Sex, Metabolic and Pharmacologic Factors May Predict Nonresponse Status to Rheumatoid Arthritis Therapies

L BORDEAN, M CHIS, AM CIMPEAN, AC BARB, AA COSMA, MP FENESAN, OS COTOI, L NICOLESCU, CM NICOLESCU, C AVRAM

In Vivo September 2023, 37 (5) 2387-2401; DOI: <https://doi.org/10.21873/invivo.13344>

10.) Reassessing Breast Cancer-Associated Fibroblasts (CAFs) Interactions with Other Stromal Components and Clinico-Pathologic Parameters by Using Immunohistochemistry and Digital Image Analysis (DIA)

Alina Cristina Barb, M Pasca Fenesan, M Pirtea, MM Margan, L Tomescu, E Ceban, AM CIMPEAN, E Melnic

Cancers **2023**, 15(15), 3823; <https://doi.org/10.3390/cancers15153823>

11.) Tertiary Lymphoid Structures (TLSSs) and Stromal Blood Vessels Have Significant and Heterogeneous Impact on Recurrence, Lymphovascular and Perineural Invasion amongst Breast Cancer Molecular Subtypes Tertiary Lymphoid Structures (TLSSs) and Stromal Blood Vessels Have Significant and Heterogeneous Impact on Recurrence, Lymphovascular and Perineural Invasion amongst Breast Cancer Molecular Subtypes

AC Barb, M Pasca Fenesan, M Pirtea, MM Margan, L Tomescu, E Melnic, Anca Maria Cimpean

Cells **2023**, 12(8), 1176; <https://doi.org/10.3390/cells12081176>

12.) Clinical Outcomes, Treatment and Testing Patterns in Patients with Advanced Non Small Lung Cell Cancer with Epidermal Growth Factor Receptor Mutations: Results of the Romanian Cohort From a Multi-national Retrospective Chart Review (REFLECT)

M Dediu, A Alexandru, C Cebotaru, B Gafton, M Marinca, A Nita, M Pașca Feneșan, G Teodorescu, TE. Ciuleanu

Journal of Medical and Radiation Oncology, Volume II, Issue 2 (December 2022) 27-37;

<https://doi.org/10.53011/JMRO.2022.02.05>

